Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Cromwell

Family Medicine Raleigh, NC Medical Doctor

NPI 1699777565 CMS profile 76394

8300 Health Park Drive, Suite 320, Raleigh, NC 27615

Open in the dashboard

General payments

$878,704

820 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,785,281 paid to institutions, not to them · program years 2024–2025

Through program year 2025, William Cromwell of Raleigh, NC is reported in the CMS Open Payments database as having received $878,704 across 820 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,785,281 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $49,866 48
2024 General $79,448 89
2023 General $83,858 74
2022 General $95,002 72
2021 General $209,769 177
2020 General $133,343 117
2019 General $227,417 243

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Cromwell
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to William Cromwell were reported at $49,866. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year William Cromwell Family Medicine median Middle half National median
2019 $227,417 $150 $41–$543 $163
2020 $133,343 $120 $32–$415 $114
2021 $209,769 $137 $35–$551 $132
2022 $95,002 $137 $37–$512 $149
2023 $83,858 $149 $42–$545 $160
2024 $79,448 $156 $44–$560 $164
2025 $49,866 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Esperion Therapeutics, Inc. $328,716 253 payments
  2. Amgen Inc. $298,234 264 payments
  3. Amarin Pharma Inc. $236,656 267 payments
  4. Merck Sharp & Dohme Corporation $6,206 5 payments
  5. Novartis Pharmaceuticals Corporation $3,536 2 payments
  6. AstraZeneca Pharmaceuticals LP $3,249 12 payments
  7. Moderna TX, Inc. $1,687 10 payments
  8. AGEPHA Pharma FZ LLC $183 1 payment
  9. AstraZeneca UK Limited $135 1 payment
  10. Boston Scientific Corporation $58 2 payments
  11. Other $45 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $710,290 295 payments
  2. Travel and Lodging $136,228 268 payments
  3. Food and Beverage $19,006 250 payments
  4. Consulting Fee $13,150 5 payments
  5. Education $31 2 payments
Products named General payments · program years 2019–2025
  1. NEXLETOL $328,716 253 payments
  2. NEXLIZET $328,292 248 payments
  3. Repatha Cardiology $251,843 221 payments
  4. Vascepa Hypertriglyceridemia $162,732 182 payments
  5. Vascepa Cardiovascular $73,924 85 payments
  6. REPATHA Cardiovascular $46,392 43 payments
  7. LODOCO $183 1 payment
  8. Artisan $58 2 payments
  9. LEQVIO $20 1 payment
  10. EVKEEZA $19 1 payment
  11. Other $26 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

106

Median for Family Practice: 1,826

Drug cost

$45,906

Median for Family Practice: $120,094

Branded share of claims

51.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Repatha Sureclick Evolocumab Brand 44 $33,494
Vascepa Icosapent Ethyl Brand 11 $11,209
Ezetimibe Generic 35 $937
Rosuvastatin Calcium Generic 16 $266

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
$45,796 44 —
NEXLETOL
$13,752 — —
NEXLIZET
$13,485 — —
LODOCO
$183 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

820 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record